PreveCeutical Medical Inc (18H) - Net Assets

Latest as of September 2025: €-7.39 Million EUR ≈ $-8.64 Million USD

Based on the latest financial reports, PreveCeutical Medical Inc (18H) has net assets worth €-7.39 Million EUR (≈ $-8.64 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€456.04K ≈ $533.16K USD) and total liabilities (€7.85 Million ≈ $9.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See PreveCeutical Medical Inc balance sheet independence to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-7.39 Million
% of Total Assets	-1621.18%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

PreveCeutical Medical Inc - Net Assets Trend (2016–2024)

This chart illustrates how PreveCeutical Medical Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of PreveCeutical Medical Inc.

Annual Net Assets for PreveCeutical Medical Inc (2016–2024)

The table below shows the annual net assets of PreveCeutical Medical Inc from 2016 to 2024. Also explore 18H net assets growth trend to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	€-6.64 Million ≈ $-7.76 Million	-14.86%
2023-12-31	€-5.78 Million ≈ $-6.76 Million	-24.66%
2022-12-31	€-4.64 Million ≈ $-5.42 Million	-12.94%
2021-12-31	€-4.10 Million ≈ $-4.80 Million	-13.88%
2020-12-31	€-3.60 Million ≈ $-4.21 Million	+19.68%
2019-12-31	€-4.49 Million ≈ $-5.25 Million	-96.34%
2018-12-31	€-2.29 Million ≈ $-2.67 Million	-563.64%
2017-12-31	€-344.34K ≈ $-402.57K	-16.31%
2016-12-31	€-296.06K ≈ $-346.13K	--

Equity Component Analysis

This analysis shows how different components contribute to PreveCeutical Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2631026300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€22.92 Million	%
Total Equity	€-6.64 Million	100.00%

PreveCeutical Medical Inc Competitors by Market Cap

The table below lists competitors of PreveCeutical Medical Inc ranked by their market capitalization.

Company	Market Cap
REDSUN PROPERTIES GROUP F:0RJ	$3.34 Million
FW Thorpe PLC LSE:TFW	$3.34 Million
EMPYREAN ENERGY LS-002 F:E1E	$3.34 Million
Archon Minerals Ltd V:ACS	$3.35 Million
Weaccess Group SA PA:MLWEA	$3.33 Million
Zephyr Minerals Ltd V:ZFR	$3.33 Million
Pembroke VCT PLC LSE:PEMB	$3.33 Million
Central Asia Metals Plc LSE:CAML	$3.33 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in PreveCeutical Medical Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -5,778,170 to -6,636,908, a change of -858,738.
Net loss of 1,174,677 reduced equity.
New share issuances of 94,697 increased equity.
Other factors increased equity by 221,242.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-1.17 Million	-17.7%
Share Issuances	€94.70K	+1.43%
Other Changes	€221.24K	+3.33%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares PreveCeutical Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€0.00	€0.01	x
2018-12-31	€-0.01	€0.01	x
2019-12-31	€-0.01	€0.01	x
2020-12-31	€-0.01	€0.01	x
2021-12-31	€-0.01	€0.01	x
2022-12-31	€-0.01	€0.01	x
2023-12-31	€-0.01	€0.01	x
2024-12-31	€-0.01	€0.01	x

Capital Efficiency Dashboard

This dashboard shows how efficiently PreveCeutical Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	0.00%	-10070.26%	0.15x	0.00x	€-3.10 Million
2017	0.00%	-32526.24%	0.01x	0.00x	€-7.20 Million
2018	0.00%	-76909.98%	0.01x	0.00x	€-11.66 Million
2019	0.00%	-118076.54%	0.00x	0.00x	€-3.13 Million
2020	0.00%	0.00%	0.00x	0.00x	€-3.44 Million
2021	0.00%	0.00%	0.00x	0.00x	€-1.32 Million
2022	0.00%	0.00%	0.00x	0.00x	€-1.02 Million
2023	0.00%	0.00%	0.00x	0.00x	€-696.65K
2024	0.00%	0.00%	0.00x	0.00x	€-510.99K

Industry Comparison

This section compares PreveCeutical Medical Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $130,681,636
Average return on equity (ROE) among peers: -39.80%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
PreveCeutical Medical Inc (18H)	€-7.39 Million	0.00%	N/A	$3.34 Million
TME PHARM.CONF.IPO EO 1- (0N6A)	$-1.27 Million	0.00%	0.00x	$10.44 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$113.23 Million	-53.64%	0.85x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$19.57 Million	-78.67%	0.35x	$141.34 Million
Theravance Biopharma Inc (0TB)	$-338.57 Million	0.00%	0.00x	$828.57 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$201.16 Million	-11.05%	0.06x	$186.58 Million
Argen-X (1AE)	$344.93 Million	-8.14%	0.08x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$39.63 Million	-145.12%	5.94x	$854.77 Million
BIOCURE TECHNOLOGY INC. (1WH)	$1.34 Million	-19.58%	0.49x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$796.12 Million	-42.03%	0.30x	$1.82 Billion

About PreveCeutical Medical Inc

F:18H Germany Biotechnology

Market Cap

$3.34 Million

€2.85 Million EUR

Market Cap Rank

#29390 Global

#2539 in Germany

Share Price

€0.01

Change (1 day)

-54.55%

52-Week Range

€0.01 - €0.03

All Time High

€0.13